ClinicalTrials.gg
CompletedNCT00404352REFLEXUpdated Jan 24, 2014Results posted

REbif FLEXible Dosing in Early Multiple Sclerosis (MS)

A Phase 3 interventional study of RNF and RNF in Multiple Sclerosis, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 67 sites in 27 countries. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2014-01-24.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
517
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing Interferon beta-1a in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis.

Enrollment
2nd of 34
517 · median 85
Started
2006
the only one that year
Phase 3
7 of 34
none open now
Registered
8th of 34
by date
Lead sponsor
6 of 34
Merck KGaA, Darmstadt, Germany

Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, this one is the 2nd largest by enrollment, is the only one that started in 2006, is one of 7 in phase 3, and was the 8th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 34 studies testing Interferon beta-1a in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies testing Interferon beta-1a in Multiple Sclerosis as a file.
02

Study summary

The study is a 24 months randomized, double-blind, Placebo-controlled, multi-center clinical trial with an optional 12 months open label extension.

The primary objective of the study is to evaluate the effect of fetal bovine serum [FBS]-free/human serum albumin [HSA]-free formulation of Interferon [IFN] beta-1a (RNF) 44 microgram (three times weekly and once weekly) versus placebo on the time to conversion to McDonald multiple sclerosis (MS) criteria (2005) in subjects with a first clinical demyelinating event at high risk of converting to MS.

The main secondary objective of study is to evaluate the effect of RNF 44 microgram (three times weekly and once weekly) versus placebo on the "Time to conversion to clinically definite MS (CDMS)" in subjects with a first clinical demyelinating event at high risk of converting to MS.

At the end of 24 month double-blind core REFLEX trial, subjects who will not convert to CDMS and decide to receive open-label (OL) treatment will be enrolled into an open-label, 12 month extension period to evaluate the effect of RNF 44 mcg three times weekly treatment on the time to conversion to McDonald MS and time to conversion to CDMS.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Rebif New Formulation
  • Clinical Isolated Syndrome
  • Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Single, first clinical event suggestive of MS within 60 days prior to study Day 1, which is the day of randomization (clock starts 24 hours after onset). The event must be a new neurological abnormality present for at least 24 hours, either mono- or polysymptomatic, other than a paresthesia, vegetative or cerebral dysfunction
  • At least two clinically silent lesions on the T2-weighted MRI scan, with a size of at least 3 millimeter (mm), at least one of which is ovoid or periventricular or infratentorial
  • EDSS 0 - 5.0 at least one time point during the screening period before start of treatment
  • 18 and 50 years old, inclusive
  • Willing to follow study procedures
  • Written
  • If female, subject must:

    • be neither pregnant nor breast-feeding nor attempting to conceive
    • use a highly effective method of . A highly effective method of contraception is defined as those which result in a low failure rate (that is [i.e.] less than 1 percent [%] per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomised partner

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of MS (per McDonald criteria 2005)
  • Any other disease that could better explain the subject's signs and symptoms
  • Complete transverse myelitis or bilateral optic neuritis
  • Subject uses or has used any other approved MS disease-modifying drug (DMD)
  • Any drug or undergone an experimental procedure within 12 weeks prior to study Day 1
  • Oral or systemic or adrenocorticotropic hormone (ACTH) within 30 days prior to study Day 1
  • Total greater than 2.5 times (ULN)
  • Subject has total (AST) or alanine aminotransferase (ALT) or alkaline phosphatase (ALP) greater than 2.5 times the ULN
  • Inadequate bone marrow reserve, defined as a total white blood cell count less than 3.0 x 109 per liter (/L), count less than 75 x 109/L, less than 100 gram per liter (g/L)
  • Current disease
  • Major medical or psychiatric illness (including history of or current severe depressive disorders and/or suicidal ideation) that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol
  • History of seizures not adequately controlled by treatment
  • Cardiac disease, such as angina, congestive heart failure or arrhythmia
  • Known allergy to IFN-beta or the (s) of the study medication
  • Any condition that could interfere with the MRI evaluation;
  • Known allergy to gadolinium-diethylene triamine pentaacetic acid (DTPA)
  • Previously participated in this study
  • Participated in any clinical trial within the past 6 months
  • Any immunomodulatory or therapy at any time prior to enrollment, including, but not limited to, the following products: any IFN, glatiramer acetate (Copolymer I), cyclophosphamide, cyclosporine, methotrexate, linomide, azathioprine, mitoxantrone, teriflunomide, laquinimod, cladribine, total lymphoid irradiation, anti-lymphocyte monoclonal antibody treatment (e.g. natalizumab, alemtuzumab/Campath, anti-cluster of differentiation 4 [CD4]), intravenous, immunoglobulins (Igs), cytokines or anti-cytokine therapy
  • Any experimental MS treatment prior to trial entry, including, but not limited to, any statins (if given to prevent MS) and pentoxyfylline
  • History of alcohol or drug abuse
  • Intolerance or any to both paracetamol (acetaminophen) and ibuprofen
  • Inability to administer subcutaneous injections either by self or by caregiver
  • Moderate to severe renal impairment
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
517 participants (actual)

Study arms

  • Active comparator
    RNF 44 mcg three times weekly

    Drug: RNF

  • Active comparator
    RNF 44 mcg once weekly and placebo twice weekly for blinding

    Drug: RNF · Drug: Placebo

  • Placebo comparator
    Placebo three times weekly

    Drug: Placebo

Interventions

  • DrugRNF

    Single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months, or 36 months for patients enrolled in the OL extension.

    Also known as: Rebif

  • DrugRNF

    Single dose of RNF administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.

    Also known as: Rebif

  • DrugPlacebo

    Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.

06

What researchers measure

Primary outcomes

  1. Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)

    The McDonald criteria use dissemination in time and space established by magnetic resonance image (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium-enhancing (Gd+) lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.

    Time frame: Various time points from randomization up to 24 months

  2. Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)

    The McDonald criteria use dissemination in time and space established by MRI findings to provide a clinical diagnosis for MS. Dissemination in time is established by a T2 or Gd+ lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.

    Time frame: Various time points from randomization up to 36 months

Secondary outcomes

  1. Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score

    CDMS was defined by the occurrence of a second exacerbation or relapse over 24 months in participants who presented with first clinical demyelinating event (FCDE) accompanied by an abnormal MRI scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.

    Time frame: Various time points from randomization up to 24 months

  2. Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score

    CDMS was defined by the occurrence of a second exacerbation or relapse over 36 months in participants who presented with FCDE accompanied by an abnormal MRI scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.

    Time frame: Various time points from randomization up to 36 months

  3. Mean Number of Combined Unique Active (CUA) Lesions, New Time Constant 2 (T2) Lesions, Gadolinium Enhanced (Gd+) Lesions and New Time Constant 1 (T1) Hypointense Lesions Per Participant Per Scan

    Number of CUA lesions, new T2 lesions, Gd+ lesions and new T1 hypointense lesions were measured by using MRI scans.

    Time frame: Month 24 up to Month 36

  4. Change From Baseline in Time Constant 2 (T2) Lesion Volume , Time Constant 1 (T1) Hypointense Lesion Volume and Gadolinium Enhanced (Gd+) Lesion Volume at Month 36

    Change from baseline in lesion volume was measured by using MRI scans for T2 lesions, T1 hypointense lesions and (Gd+) lesions.

    Time frame: Baseline, Month 36

  5. Change From Baseline in Expanded Disability Status Score (EDSS) Score at Month 36

    EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. The change in EDSS at Month 36 was calculated as EDSS at Month 36 minus EDSS at baseline.

    Time frame: Baseline, Month 36

07

Results

Posted Sep 24, 2012

Participant flow

The participants were recruited in 78 centers across 28 countries for REFLEX study. REFLEX 12 months open label extension (OLE) was conducted at 11 active centers in 9 countries.

Double Blind (up to 24 Month)
Participant flow — Double Blind (up to 24 Month)
MilestoneRNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)RNF 44 Mcg Once Weekly (DB Population)Placebo (DB Population)RNF 44 Mcg Three Times Weekly/OL RNF 44 Mcg Three Times WeeklyRNF 44 Mcg Once Weekly/OL RNF 44 Mcg Three Times WeeklyPlacebo/OL RNF 44 Mcg Three Times WeeklyRNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)Placebo/RNF 44 Mcg Three Times Weekly (OLE)
Started171175171000000
Treated171173171000000
Completed11912892000000
Not completed524779000000
Withdrew: Adverse event546000000
Withdrew: Pregnancy002000000
Withdrew: Death001000000
Withdrew: Lost to follow-up121000000
Withdrew: Withdrawal by subject1187000000
Withdrew: Disease progression302000000
Withdrew: Poor compliance100000000
Withdrew: Switched to open label phase313059000000
Withdrew: Randomized but not treated020000000
Withdrew: Physician decision001000000
Withdrew: Other010000000
Open Label (up to 24 Month)
Participant flow — Open Label (up to 24 Month)
MilestoneRNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)RNF 44 Mcg Once Weekly (DB Population)Placebo (DB Population)RNF 44 Mcg Three Times Weekly/OL RNF 44 Mcg Three Times WeeklyRNF 44 Mcg Once Weekly/OL RNF 44 Mcg Three Times WeeklyPlacebo/OL RNF 44 Mcg Three Times WeeklyRNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)Placebo/RNF 44 Mcg Three Times Weekly (OLE)
Started000313059000
Completed000282852000
Not completed000327000
Withdrew: Adverse event000211000
Withdrew: Pregnancy000001000
Withdrew: Lost to follow-up000010000
Withdrew: Withdrawal by subject000005000
Withdrew: Disease progression000100000
Open Label Extension (up to 36 Months)
Participant flow — Open Label Extension (up to 36 Months)
MilestoneRNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)RNF 44 Mcg Once Weekly (DB Population)Placebo (DB Population)RNF 44 Mcg Three Times Weekly/OL RNF 44 Mcg Three Times WeeklyRNF 44 Mcg Once Weekly/OL RNF 44 Mcg Three Times WeeklyPlacebo/OL RNF 44 Mcg Three Times WeeklyRNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)Placebo/RNF 44 Mcg Three Times Weekly (OLE)
Started0000004511
Completed000000349
Not completed000000112
Withdrew: Adverse event000000110
Withdrew: Other000000002

Outcome measures

PrimaryTime to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)

The McDonald criteria use dissemination in time and space established by magnetic resonance image (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium-enhancing (Gd+) lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.

Time frame:
Various time points from randomization up to 24 months
Reported as:
Median · days
Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)
daysRNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)RNF 44 Mcg Once Weekly (DB Population)Placebo (DB Population)
Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)310 (183 to 488)182 (107 to 270)97 (93 to 101)
Statistical analysis
  • RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population) vs Placebo (DB Population) · Log Rank · p = <0.001Log-rank test was stratified for controlling randomization stratification factors.
  • RNF 44 Mcg Once Weekly (DB Population) vs Placebo (DB Population) · Log Rank · p = 0.008Log-rank test was stratified for controlling randomization stratification factors.
  • RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population) vs RNF 44 Mcg Once Weekly (DB Population) · Log Rank · p = 0.009Log-rank test was stratified for controlling randomization stratification factors.
SecondaryTime to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score

CDMS was defined by the occurrence of a second exacerbation or relapse over 24 months in participants who presented with first clinical demyelinating event (FCDE) accompanied by an abnormal MRI scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.

Time frame:
Various time points from randomization up to 24 months
Reported as:
Median · days
Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score
daysRNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)RNF 44 Mcg Once Weekly (DB Population)Placebo (DB Population)
Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) ScoreNA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population) vs Placebo (DB Population) · Log Rank · p = <0.001Log-rank test was stratified for controlling randomization stratification factors.
  • RNF 44 Mcg Once Weekly (DB Population) vs Placebo (DB Population) · Log Rank · p = 0.002Log-rank test was stratified for controlling randomization stratification factors.
  • RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population) vs RNF 44 Mcg Once Weekly (DB Population) · Log Rank · p = 0.774Log-rank test was stratified for controlling randomization stratification factors.
SecondaryTime to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score

CDMS was defined by the occurrence of a second exacerbation or relapse over 36 months in participants who presented with FCDE accompanied by an abnormal MRI scan. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.

Time frame:
Various time points from randomization up to 36 months
Reported as:
Median · days
Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) Score
daysRNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)Placebo/RNF 44 Mcg Three Times Weekly (OLE)
Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) Defined by Either a Second Attack or a 3-Month Sustained Increase (Greater Than or Equal to 1.5 Points) in the Expanded Disability Status Scale (EDSS) ScoreNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryMean Number of Combined Unique Active (CUA) Lesions, New Time Constant 2 (T2) Lesions, Gadolinium Enhanced (Gd+) Lesions and New Time Constant 1 (T1) Hypointense Lesions Per Participant Per Scan

Number of CUA lesions, new T2 lesions, Gd+ lesions and new T1 hypointense lesions were measured by using MRI scans.

Time frame:
Month 24 up to Month 36
Reported as:
Mean · lesions
Mean Number of Combined Unique Active (CUA) Lesions, New Time Constant 2 (T2) Lesions, Gadolinium Enhanced (Gd+) Lesions and New Time Constant 1 (T1) Hypointense Lesions Per Participant Per Scan
lesionsRNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)Placebo/RNF 44 Mcg Three Times Weekly (OLE)
CUA lesions (n=3,5,9)0.33 ± 0.580.00 ± 0.001.56 ± 2.93
New T2 lesions (n=3,5,9)0.17 ± 0.290.00 ± 0.000.94 ± 1.61
New Gd+ lesions (n=3,5,9)0.17 ± 0.290.00 ± 0.000.56 ± 1.21
New T1 Hypointense lesions (n=3,5,9)0.17 ± 0.290.00 ± 0.000.56 ± 0.88
SecondaryChange From Baseline in Time Constant 2 (T2) Lesion Volume , Time Constant 1 (T1) Hypointense Lesion Volume and Gadolinium Enhanced (Gd+) Lesion Volume at Month 36

Change from baseline in lesion volume was measured by using MRI scans for T2 lesions, T1 hypointense lesions and (Gd+) lesions.

Time frame:
Baseline, Month 36
Reported as:
Mean · cubic millimeter (mm^3)
Change From Baseline in Time Constant 2 (T2) Lesion Volume , Time Constant 1 (T1) Hypointense Lesion Volume and Gadolinium Enhanced (Gd+) Lesion Volume at Month 36
cubic millimeter (mm^3)RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)Placebo/RNF 44 Mcg Three Times Weekly (OLE)
T2 lesion volume at Baseline (n=4,5,11)675.20 ± 940.871703.48 ± 1324.413533.37 ± 3914.98
T2 lesion volume change at Month 36 (n=2,4,8)180.25 ± 198.34-22.63 ± 382.14-1155.63 ± 3348.36
T1 lesion volume at Baseline (n=4,5,11)30.05 ± 60.10302.70 ± 358.58488.72 ± 589.06
T1 lesion volume change at Month 36 (n=2,4,8)55.75 ± 78.84216.68 ± 310.06138.89 ± 339.99
Gd+ lesion volume at Baseline (n=4,5,11)103.70 ± 151.170.00 ± 0.00287.15 ± 649.68
Gd+ lesion volume change at Month 36 (n=2,4,8)-47.20 ± 66.750.00 ± 0.00-246.08 ± 848.99
PrimaryTime to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)

The McDonald criteria use dissemination in time and space established by MRI findings to provide a clinical diagnosis for MS. Dissemination in time is established by a T2 or Gd+ lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions.

Time frame:
Various time points from randomization up to 36 months
Reported as:
Median · days
Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)
daysRNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)Placebo/RNF 44 Mcg Three Times Weekly (OLE)
Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryChange From Baseline in Expanded Disability Status Score (EDSS) Score at Month 36

EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. The change in EDSS at Month 36 was calculated as EDSS at Month 36 minus EDSS at baseline.

Time frame:
Baseline, Month 36
Reported as:
Mean · unit on a scale
Change From Baseline in Expanded Disability Status Score (EDSS) Score at Month 36
unit on a scaleRNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)Placebo/RNF 44 Mcg Three Times Weekly (OLE)
Baseline (n=4,5,11)1.88 ± 0.851.60 ± 0.961.64 ± 0.67
Change at Month 36 (n=2,4,8)-0.25 ± 1.06-0.63 ± 0.48-0.50 ± 0.65

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)—6/171 (3.5%)149/171 (87.1%)
RNF 44 Mcg Once Weekly (DB Population)—8/173 (4.6%)156/173 (90.2%)
Placebo (DB Population)—12/171 (7%)133/171 (77.8%)
RNF 44 Mcg Three Times Weekly/OL RNF 44 Mcg Three Times Weekly—1/31 (3.2%)20/31 (64.5%)
RNF 44 Mcg Once Weekly/OL RNF 44 Mcg Three Times Weekly—0/30 (0%)20/30 (66.7%)
Placebo/OL RNF 44 Mcg Three Times Weekly—1/59 (1.7%)47/59 (79.7%)
RNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)—0/4 (0%)3/4 (75%)
RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)—0/5 (0%)2/5 (40%)
Placebo/RNF 44 Mcg Three Times Weekly (OLE)—0/11 (0%)5/11 (45.5%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventRNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)RNF 44 Mcg Once Weekly (DB Population)Placebo (DB Population)RNF 44 Mcg Three Times Weekly/OL RNF 44 Mcg Three Times WeeklyRNF 44 Mcg Once Weekly/OL RNF 44 Mcg Three Times WeeklyPlacebo/OL RNF 44 Mcg Three Times WeeklyRNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)Placebo/RNF 44 Mcg Three Times Weekly (OLE)
CholelithiasisHepatobiliary disorders0/1710/1730/1711/310/300/590/40/50/11
AppendicitisInfections and infestations3/1710/1730/1710/310/300/590/40/50/11
Psychotic disorderPsychiatric disorders0/1710/1730/1710/310/301/590/40/50/11
Ovarian cystReproductive system and breast disorders0/1710/1732/1710/310/300/590/40/50/11
TonsillitisInfections and infestations1/1710/1730/1710/310/300/590/40/50/11
Gastrointestinal motility disorderGastrointestinal disorders0/1710/1731/1710/310/300/590/40/50/11
Inguinal herniaGastrointestinal disorders0/1710/1731/1710/310/300/590/40/50/11
Pancreatic necrosisGastrointestinal disorders0/1710/1731/1710/310/300/590/40/50/11
Breast cancer stage IIINeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1710/1731/1710/310/300/590/40/50/11
Ovarian germ cell teratoma benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1710/1731/1710/310/300/590/40/50/11
Most frequent other events
Showing 10 of 49
Most frequent other events
EventRNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)RNF 44 Mcg Once Weekly (DB Population)Placebo (DB Population)RNF 44 Mcg Three Times Weekly/OL RNF 44 Mcg Three Times WeeklyRNF 44 Mcg Once Weekly/OL RNF 44 Mcg Three Times WeeklyPlacebo/OL RNF 44 Mcg Three Times WeeklyRNF 44Mcg Three Times Weekly/RNF 44Mcg Three Times Weekly(OLE)RNF 44 Mcg Once Weekly/RNF 44 Mcg Three Times Weekly (OLE)Placebo/RNF 44 Mcg Three Times Weekly (OLE)
Influenza like illnessGeneral disorders93/171122/17334/1718/313/3024/591/41/51/11
Injection site erythemaGeneral disorders50/17134/1733/1714/313/3013/590/40/50/11
HeadacheNervous system disorders46/17137/17346/1713/312/305/591/40/52/11
SyncopeNervous system disorders0/1710/1730/1710/310/300/591/40/50/11
LymphopeniaBlood and lymphatic system disorders0/1710/1730/1710/310/300/591/40/51/11
HyperthyroidismEndocrine disorders0/1710/1730/1710/310/300/591/40/51/11
Aphthous stomatitisGastrointestinal disorders0/1710/1730/1710/310/300/591/40/50/11
Facial bones fractureInjury, poisoning and procedural complications0/1710/1730/1710/310/300/591/40/50/11
ContusionInjury, poisoning and procedural complications0/1710/1730/1710/310/300/591/40/50/11
Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1710/1730/1710/310/300/591/40/50/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)RNF 44 Mcg Once Weekly (DB Population)Placebo (DB Population)Total
Mean30.6 ± 8.530.7 ± 8.130.9 ± 7.930.7 ± 8.2
Age, Customized
Age, Customized(participants)RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)RNF 44 Mcg Once Weekly (DB Population)Placebo (DB Population)Total
Less than 30 years868687259
Greater than or equal to 30 years858984258
Sex: Female, Male
Sex: Female, Male(Participants)RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)RNF 44 Mcg Once Weekly (DB Population)Placebo (DB Population)Total
Female114106112332
Male576959185
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)RNF 44 Mcg Once Weekly (DB Population)Placebo (DB Population)Total
Asian0000
Black0101
White171174171516
Other0000
08

Study locations

67 sites
  • Research Site
    Mendoza, Argentina
  • Research Site
    Sydney, Australia
  • Research Site
    Graz, Austria
  • Research Site
    Innsbruck, Austria
  • Research Site
    B-Leuven, Belgium
  • Research Site
    Brugge, Belgium
  • Research Site
    Pleven, Bulgaria
  • Research Site
    Rousse, Bulgaria
  • Research Site
    Shumen, Bulgaria
  • Research Site
    Sofia, Bulgaria
  • Research Site
    Varna, Bulgaria
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Ontario, Canada
  • Research Site
    Victoria British Columbia, Canada
  • Research Site
    Karlovac, Croatia
  • Research Site
    Osijek, Croatia
  • Research Site
    Rijeka, Croatia
  • Research Site
    Split, Croatia
  • Research Site
    Zagreb, Croatia
  • Research Site
    Hradec Kralove, Czech Republic
  • Research Site
    Olomouc, Czech Republic
  • Research Site
    Prague, Czech Republic
  • Research Site
    Tallinn, Estonia
  • Research Site
    Tartu, Estonia
  • Research Site
    OYS, Finland
  • Research Site
    Vantaa, Finland
  • Research Site
    Paris, France
  • Research Site
    Poissy Cedex, France
  • Research Site
    Hannover, Germany
  • Research Site
    Henningsdorf, Germany
  • Research Site
    Munich, Germany
  • Research Site
    Athens, Greece
  • Research Site
    Ness Ziona, Israel
  • Research Site
    Safed, Israel
  • Research Site
    Tel-Hashomer, Israel
  • Research Site
    Catania, Italy
  • Research Site
    Milano, Italy
  • Research Site
    Padova, Italy
  • Research Site
    Roma, Italy
  • Research Site
    Riga, Latvia
  • Research Site
    Beirut, Lebanon
  • Research Site
    Rabat, Morocco
  • Research Site
    Bialystok, Poland
  • Research Site
    Lodz, Poland
  • Research Site
    Warsaw, Poland
  • Research Site
    Wroclaw, Poland
  • Research Site
    Lisboa, Portugal
  • Research Site
    Bucharest, Romania
  • Research Site
    Iasi, Romania
  • Research Site
    Targu-Mures, Romania
  • Research Site
    Timisoara, Romania
  • Research Site
    Ekaterinburg, Russian Federation
  • Research Site
    Moscow, Russian Federation
  • Research Site
    Nizhny Novgorod, Russian Federation
  • Research Site
    Novosibirsk, Russian Federation
  • Research Site
    Saint-Petersburg, Russian Federation
  • Research Site
    Samara, Russian Federation
  • Research Site
    Saratov, Russian Federation
  • Research Site
    Riyadh, Saudi Arabia
  • Research Site
    Belgrade, Serbia
  • Research Site
    Nis, Serbia
  • Research Site
    Presov, Slovakia
  • Research Site
    Barcelona, Spain
  • Research Site
    Bilbao, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Sevilla, Spain
  • Research Site
    Istanbul, Turkey
09

References and documents

Publications

  • Battaglini M, Vrenken H, Tappa Brocci R, Gentile G, Luchetti L, Versteeg A, Freedman MS, Uitdehaag BMJ, Kappos L, Comi G, Seitzinger A, Jack D, Sormani MP, Barkhof F, De Stefano N. Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a. Eur J Neurol. 2022 Jul;29(7):2024-2035. doi: 10.1111/ene.15314. Epub 2022 Apr 4. PubMed 35274413 ↗
  • Freedman MS, De Stefano N, Barkhof F, Polman CH, Comi G, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Lehr L, Stubinski B, Jack DL, Kappos L. Patient subgroup analyses of the treatment effect of subcutaneous interferon beta-1a on development of multiple sclerosis in the randomized controlled REFLEX study. J Neurol. 2014 Mar;261(3):490-9. doi: 10.1007/s00415-013-7222-6. Epub 2014 Jan 12. PubMed 24413638 ↗
  • De Stefano N, Comi G, Kappos L, Freedman MS, Polman CH, Uitdehaag BM, Hennessy B, Casset-Semanaz F, Lehr L, Stubinski B, Jack DL, Barkhof F. Efficacy of subcutaneous interferon beta-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):647-53. doi: 10.1136/jnnp-2013-306289. Epub 2013 Nov 29. PubMed 24292999 ↗
  • Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012 Jan;11(1):33-41. doi: 10.1016/S1474-4422(11)70262-9. Epub 2011 Dec 4. Erratum In: Lancet Neurol. 2012 Feb;11(2):125. PubMed 22146409 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Aug 2010 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2006
First posted
Nov 28, 2006
Start
Nov 2006
Primary completionActual
Aug 2010
CompletionActual
Jul 2011
Results first posted
Sep 24, 2012
Last update
Jan 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00404352
Responsible party
Sponsor
First posted
Nov 28, 2006
Start date
Nov 2006
Primary completion
Aug 2010
Completion
Jul 2011
Results posted
Sep 24, 2012
Last update
Jan 24, 2014

Study contacts

Bettina M. Stubinski, MD
study director · Merck Serono S.A., Geneva

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion